Exyte increases order intake, sales, and profitability

  • Order consumption of more than 25% per year, marking a new mark 9 M– up to € 6.5 billion

  • Sales volume increased by almost 60% to 5.3 billion euros

  • Strong growth in sales in all three business segments

  • Adjusted EBIT increased by 73% to €308 million; Adjusted EBITDA rose by 70% to €340 million

  • The acquisition of Airgard Inc., enhances the strategic product portfolio of the technology and services business

  • New employer brand to attract new talent

STUTTGART, Germany, November 9, 2022 /PRNewswire/ — Exyte GmbH (Exyte), a global leader in the design, engineering, and delivery of high-tech equipment, continues its strong performance in the first nine months of the current fiscal year 2022 very well. and his way of growing up, ‘his way to ten’.

Exyte_Logo

Exyte_Logo

In the first nine months of 2022, Exyte recorded an increase of almost 60% year-on-year in sales. Sales totaled around 5.3 billion euros on a regular basis (9 M/2021: €3.4 billion) thanks to high performance in all business segments especially in the APAC and EMEA regions. Both regions also contributed significantly to the system’s adoption. From January to September, consumption amounted to 6.5 billion euros (9 M/2021: €5.1 billion), an increase of more than 25% compared to the previous year.

With adjusted EBITDA of €340 million (9 M/ 2021: €200 million) and adjusted EBIT of €308 million (9 M/2021: €178 million) Exyte improved its profit. Adjusted EBITDA margin reached 6.4% (9 M/2021: 5.9%), adjusted EBIT margin reached 5.8% (9 M/2021: 5.3%), both increase by 0.5% points per year.

“The continued success of our business shows our strong position. The companies we serve continue to make steady investments. Despite the current global economic development a, we do not expect that there will be a big return for these companies or for our business. We are serving global megatrends that will continue. to expand despite the financial crisis and long-term increase, “Dr. says Wolfgang Büchele, CEO of Exyte.

Also Read :  My boyfriend has a nicer house, and says I should live with him. My mortgage is paid off. He believes I should pay half of his monthly costs. Is that fair?

The right idea despite the current economic development

“Exyte is well on its ‘Pathway to Ten’. Our target turnover of about 7 billion euros in 2022 brings us closer to our goal of reaching 10 billion sales in 2027. Working on well running with a compensation system of € 8.2 billion, Despite the ongoing economic situation, we see a positive development for Exyte,” says Peter Schönhofer, CFO of Exyte. “However, we are closely monitoring developments and their impact on our business and taking preventative measures where necessary.”

Exyte supports positive thinking at the end of the year. Based on the increase in sales, an increase in adjusted EBITDA and adjusted EBIT is expected. For 2022 the company forecasts an adjusted EBITDA of about 450 million euros, an adjusted EBIT of more than 400 million euros.

Growth in all business sectors, Biopharma & Life Sciences and Data Center with significant market development

In the first nine months of 2022 all three business units saw significant new employment across all regions. With a market share of about 87% of the group’s total sales, the business sector High tech companies recorded a sales increase of around 55% to 4.6 billion euros (9 M/2021: €3.0 billion). With the continued positive development of the semiconductor industry incoming orders have increased by almost a quarter to 5.5 billion euros (9 M/2021: 4.5 billion euros). Battery manufacturers also benefit from Exyte’s expertise in clean and dry rooms. Exyte sees other market opportunities in this business in the coming years, as the so-called gigafabs are planned for the production of batteries and batteries worldwide.

Biopharma & Life Sciences sales nearly doubled in the first nine months. The price of the part amounts to 477 million euros (9 M/2021: €247 million) due to the large work and Singapore and Malaysia. Biopharma & Life Sciences accounts for 9.0% of the group’s total sales.9 M/2021: 7.3%). Food consumption amounted to 477 million euros (9 M/2021: €384 million). Inside Germany, Exyte is building an mRNA license center in Halle. Other biopharma projects are also being prepared for the global pharmaceutical industry. Exyte recently opened a new Life Sciences Office Cork, Ireland. The Irish pharmaceutical sector has grown rapidly in recent years. Exyte expects to invest heavily in it Ireland and projects from biotechnology to complete completion, Functional medicine and cell and gene therapy.

Also Read :  St. Lucia’s economy is all set to blast off after Japan’s $23 million booster shot

Price of Data source Shares rose by 74% to €181 million (9 M/2021: €104 million). The consumption increased by more than 130% to 409 million euros (9 M/2021: €175 million). The business segment currently operates a data center and Austria, Denmark, Germany, Israel, Malaysiaand Taiwanamong others.

Strategic growth of technology in the service sector

Exyte recently acquired Airgard Inc., a US-based specialist in gas cleaning technology. Airgard waterproof towels are used worldwide by leading players in the semiconductor industry. The acquisition of Airgard strengthens Exyte’s position to support its customers with technical solutions for their exhaust control, also due to the increasing standards that come with environmental, social and governmental (ESG) standards.

This is another acquisition in which Exyte builds its strategy of vertical integration by strengthening its business in areas of critical technology and services. In 2021, Exyte acquired the Critical Process Systems Group and made it part of the Technology & Services (T&S) Business Area. T&S has companies that provide cleanroom technology, installation services, and equipment necessary for its customers’ subsystems and outside manufacturing (OSM). In the first nine months of Technology & Services 2022 sales almost doubled to 555 million.9 M/ 2021: € 280 million) contributing approximately 10% to the group’s total sales (9 M/2021: 8.0%). Imports more than doubled to €788 million (9 M/2021: €336 million).

Also Read :  Market Rally Buckling From Fed, Apple, Tesla, Cloud Stocks; What To Do Now

Success in the ‘Ten Way’ – New Employer Branding

Targeted, strategic acquisitions are the cornerstone of Exyte’s future Agenda ‘Next Level’. In this plan, the company has identified several areas of practice to be successful in its ‘Pathway to Ten’. Another aspect of action is to become an employer of choice for existing and future employees. To this end, Exyte recently introduced a new employee brand that is the basis for acquiring and recruiting global talent. It is expected that 15,000 employees will work for Exyte in 2027, more than double the number in 2021. At the end of September 2022 Exyte employs nearly 9,000 people worldwide.

Basic accounting and checking

9M/2022

9M/2021

Change

2022 vs 2021

Order acceptance

€6.5bn

€5.1bn

+26.1%*

Price

€5.3bn

€3.4bn

+57.0%*

Adjusted EBITDA

€340m

€200m

+70.0%

Adjusted EBITDA margin

6.4%

5.9%

+ 0.5 PP

Adjusted EBIT

€308m

€178m

+73.0%

Adjusted EBIT margin

5.8%

5.3%

+ 0.5 PP

* Percentages are calculated based on values ​​in millions.

For more details about 9 M-results 2022 please visit exyte.net website.

About Exyte

Exyte is a global leader in the design, engineering and delivery of clean and sustainable equipment for the high technology industry. With expertise developed over a century, we serve customers in the advanced markets of semiconductors, battery cells, pharmaceuticals, biotechnology and data centers. Exyte offers a wide range of services from research to managing the implementation of turnkey solutions with the highest standards in safety and quality to our customers worldwide. We are creating a better future by promoting key industries to improve the quality of modern life. In 2021, Exyte created a market of 4.9 billion euros with 7,400 employees around the world.

Contact:

René Ziegler
Vice President of Communications and Business Relations
+49 711 88044606
+49 172 5838786
[email protected]
www.exyte.net

Logo: https://mma.prnewswire.com/media/1487100/Exyte_Logo.jpg

Cision

Cision

View original content: https://www.prnewswire.co.uk/news-releases/strong-business-performance-in-9m2022-exyte-increases-order-intake-sales-and-profitability-301672765.html

Source

Leave a Reply

Your email address will not be published.

Related Articles

Back to top button